Diagnostics Solutions Strategic Priorities slide image

Diagnostics Solutions Strategic Priorities

Supporting patient journeys with our oncology portfolio Sales of oncology reagents surpassing CHF 1.8 bn in 2020 Roche Screening Diagnosis & Classification Prognosis¹ Therapy selection² Monitoring/Surveillance 8 250+ 5 2 1 10 7 5 3 13 1 www IA (CA 19-9) A IHC (Ki67) Π PCR (EGFR) Algorithms IA (CA 19-9) IHC (Ki67) PCR (EGFR) Algorithms IA (CA 19-9) IHC (Ki67) NGS Algorithms IA (CA 19-9) IHC (Ki67) PCR (EGFR) NGS Algorithms IA (CA 19-9) PCR (EGFR) NGS Algorithms 3 1 1 1 Predicting the likely or expected development of a disease 2 On-label CDx indications Polymerase Chain Reaction (PCR) Algorithms Decision support: NAVIFY Mutation Profiler, NAVIFY Tumor Board, NAVIFY guidelines Immunoassay (IA) Immunohistochemistry (IHC) Next Gen Sequencing (NGS) XIM 64 64
View entire presentation